#VELA Vela Technologies Plc – EXERCISE OF PUT OPTION December 1, 2023 – Posted in: Tiziana Life Sciences (TILS), Vela Technologies Plc (VELA)

Exercise of Put Option for sale of Economic Interest in AZD1656 Highlights: · Exercised the put option agreement to sell its economic interest in AZD1656 for shares in Conduit Pharmaceuticals Inc. · The stake held by Vela is now valued at approximately £3.75 million (based on the closing share price of Conduit at 30 November 2023) compared to the fair value of £2.35 million reported at the last audited balance sheet date of 31…

Tiziana Life Sciences – Announces Plants to List Accustem Sciences in the US April 13, 2021 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Life Sciences plc Announces Plans to List Accustem Sciences Limited in the U.S. NEW YORK and LONDON, April 13, 2021 – Tiziana Life Sciences plc (NASDAQ: TLSA; LSE: TILS), today announced that its former subsidiary, Accustem Sciences Limited (“Accustem”), intends to file a listing application with the Nasdaq Stock Market shortly after completion of the distribution of shares in Accustem to Tiziana Life Sciences plc shareholders. The board of directors of…

Tiziana Life Sciences – Appointment of Director February 5, 2021 – Posted in: Tiziana Life Sciences (TILS)

5th February, 2021 APPOINTMENT OF DIRECTOR Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces the appointment of Dr Thomas Adams, Ph.D. as an executive director. Dr Adams will assume the position of Head of Drug Development with immediate effect and his executive role will be to manage and oversee all matters relating to the Company’s pre-clinical and clinical…

Tiziana Life Sciences – CEO interview February 3, 2021 – Posted in: Tiziana Life Sciences (TILS), Uncategorized

3rd February, 2021 Tiziana Life Sciences CEO Discusses COVID-19 Trial Data in Exclusive Interview Tiziana Life Sciences plc (NASDAQ:TLSA/LSE:TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced an interview with Dr. Kunwar Shailubhai, CEO and CSO, is now available. In the exclusive interview, Dr. Shailubhai discusses the positive effect of nasally administered Foralumab in COVID-19 mediated pulmonary and systemic inflammation and its potential related…

Tiziana Life Sciences – Positive Data from Clinical Study of Nasal Administration with Foralumab February 2, 2021 – Posted in: Tiziana Life Sciences (TILS)

2nd February, 2021 THIS ANNOUNCEMENT INCLUDES INSIDE INFORMATION Tiziana Reports Positive Data from the Clinical Study of Nasal Administration with Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, in COVID-19 Patients in Brazil · Since the anti-inflammatory effect of the nasally administered Foralumab is through the modulation of the immune system and not by directly targeting COVID-19, this therapeutic approach might also be useful for newly identified Covid-19 variants in UK, South Africa and Brazil. · Foralumab is also the first monoclonal…

Tiziana Life Sciences – Files Registration Statement on Form F-3 with SEC January 27, 2021 – Posted in: Tiziana Life Sciences (TILS)

27th January, 2021 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana files Registration Statement on Form F-3 with U.S. Securities and Exchange Commission Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces that it has filed a “universal” shelf registration statement on Form F-3 (File No. 333-252441) (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) in relation to…

Tiziana Life Sciences – Updated Corporate Presentation January 26, 2021 – Posted in: Tiziana Life Sciences (TILS)

26 January 2021 Updated corporate presentation Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, has today published an updated presentation to its website at https://ir.tizianalifesciences.com/presentation providing an update with respect to an overview of its current clinical pipeline. The presentation contains no new material information but gives an overview of all of the Company’s current and active development…

Tiziana Life Sciences – AIM Delisting and Admission to the Standard Listing Segment of Main Market January 20, 2021 – Posted in: Tiziana Life Sciences (TILS)

20th January, 2021 Tiziana Life Sciences plc (“Tiziana” or the “Company”) AIM Delisting and Admission to the Standard Listing Segment of Main Market Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today provided a further update with respect to the cancellation of admission of its Ordinary Shares to trading on AIM and admission to listing of its ordinary…

Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer January 13, 2021 – Posted in: Tiziana Life Sciences (TILS)

13th January, 2021 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer. Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist…

Tiziana Life Sciences to Host Investor Update Call December 1, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences to Host Investor Update Call on 2 December 2020 at 4:15 p.m. ET NEW YORK and LONDON – 1 December 2020 (GLOBE NEWSWIRE) – Tiziana Life Sciences plc (NASDAQ: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced its CEO and CSO Dr. Kunwar Shailubhai will host a conference call on Wednesday, 2 December 2020 at 4:15 p.m. ET to provide updates on…

1
2
3
4
5
...
11
Next
Last »